Acer Therapeutics Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$25.9M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Acer Therapeutics's estimated annual revenue is currently $5M per year.(i)
  • Acer Therapeutics received $11.0M in venture funding in December 2017.
  • Acer Therapeutics's estimated revenue per employee is $111,667
  • Acer Therapeutics's total funding is $25.9M.

Employee Data

  • Acer Therapeutics has 45 Employees.(i)
  • Acer Therapeutics grew their employee count by 61% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$413.3M344-2%$634MN/A
#2
$49.6M247-6%N/AN/A
#3
$10.7M53130%N/AN/A
#4
$20.1M10023%$113MN/A
#5
$4M48118%N/AN/A
#6
$1.8M4063%$538MN/A
#7
$40.2M200-11%N/AN/A
#8
$11.6M192-14%$506.4MN/A
#9
$3.7M4588%N/AN/A
#10
$4360M45081175%N/AN/A

Acer Therapeutics Inc. (Nasdaq: ACER) is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with critical unmet medical need. Founded in 2013, Acer completed its Initial Public Offering in 2017, has raised $87M to date, and has rapidly built a diverse portfolio of product candidates. Our pipeline includes three clinical-stage candidates: EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; ACER-001 (a fully taste-masked, immediate release formulation of sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCD) and Maple Syrup Urine Disease (MSUD); and osanetant for the treatment of various neuroendocrine disorders. On December 26, 2018 the U.S. Food and Drug Administration (FDA) accepted for review Acer's New Drug Application (NDA) for EDSIVO for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed COL3A1 mutation. The FDA also granted a priority review of the NDA and assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 25, 2019. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Acer's strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency. Acer has a strong company culture and is committed to creating and maintaining an environment that values individual rights, hard work, fosters creativity, and promotes success. The Company is growing rapidly and is fueled by the talent and expertise of our employees, driven by the commitment to treating patients with critical unmet medical needs.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$25.9M

Total Funding

45

Number of Employees

$5M

Revenue (est)

61%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Acer Therapeutics News

2022-04-17 - Acer Therapeutics Inc. (NASDAQ:ACER) Short Interest Update

On average, equities research analysts anticipate that Acer Therapeutics will post -2.05 earnings per share for the current fiscal year. Hedge...

2022-04-13 - Acer Therapeutics and Relief Therapeutics Announce ...

Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting.

2022-03-30 - Acer Therapeutics Enrolls First Patient in its Phase 2a Clinical ...

NEWTON, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition...

2021-10-07 - Acer Therapeutics : Notice of allowance of ACER-001 formulation composition of matter patent application strengthens proprietary position in U.S. until 2036 (Form 8-K)

Notice of allowance of ACER-001 formulation composition of matter patent application strengthens proprietary position in U.S. until 2036 NEWTON, MA and GENEVA, SWITZERLAND - October 7, 2021 - Acer Therapeutics Inc. (Nasdaq: ACER) ("Acer") and its collaboration partner, Relief Therapeutics Holdi ...

2021-10-07 - Acer Therapeutics Receives Notice of Allowance of Key U.S. Patent Application Covering ACER-001 Formulation

EQS Group-Ad-hoc: RELIEF THERAPEUTICS Holding AG / Key word(s): Patent Acer Therapeutics Receives Notice of Allowance of Key U.S. Patent Application Covering ACER-001 Formulation 07-Oct-2021 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsibl ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.3M452%N/A
#2
$7.3M462%$39.8M
#3
$9.6M4727%N/A
#4
$6.6M47-11%N/A
#5
$15M477%N/A

Acer Therapeutics Funding

DateAmountRoundLead InvestorsReference
2016-05-11$8.2MBTVM Life Science Venture VIIArticle
2017-12-18$11.0MUndisclosedWilliam Blair & Company, L.L.C.Article